Diabetic ketoacidosis during COVID-19 pandemic in a developing country

We read with interest the study published by Goldman et al [1], who identified four patients with diabetic ketoacidosis (DKA) resistant to standard therapy that was triggered by COVID-19 and was associated with high morbidity and mortality. This is also happening in developing countries such as Peru, which has the highest number of COVID-19 cases per million inhabitants and the second-lowest public healthcare spending according to WHO [2].

Source: Diabetes Research and Clinical Practice - August 23, 2020 Category: Endocrinology Authors: Marcio Jos é Concepción Zavaleta, Cristian David Armas Flórez, Esteban Alberto Plasencia Dueñas, Julia Cristina Coronado Arroyo Tags: Letter to the Editor Source Type: research